Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Exchange Rate Effect: 2021-2025

Historic Exchange Rate Effect for Arrowhead Pharmaceuticals (ARWR) over the last 4 years, with Sep 2025 value amounting to -$24,000.

  • Arrowhead Pharmaceuticals' Exchange Rate Effect fell 100.55% to -$24,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$401,000, marking a year-over-year decrease of 109.55%. This contributed to the annual value of -$401,000 for FY2025, which is 109.55% down from last year.
  • According to the latest figures from Q3 2025, Arrowhead Pharmaceuticals' Exchange Rate Effect is -$24,000, which was down 125.81% from $93,000 recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Exchange Rate Effect registered a high of $4.3 million during Q3 2024, and its lowest value of -$402,000 during Q1 2025.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Exchange Rate Effect value was -$24,000 (recorded in 2025), while the average stood at $345,091.
  • Over the last 5 years, Arrowhead Pharmaceuticals' Exchange Rate Effect had its largest YoY gain of 5,000.00% in 2023, and its largest YoY loss of 7,500.00% in 2023.
  • Arrowhead Pharmaceuticals' Exchange Rate Effect (Quarterly) stood at -$39,000 in 2021, then tumbled by 212.82% to -$122,000 in 2022, then skyrocketed by 147.54% to $58,000 in 2023, then tumbled by 217.24% to -$68,000 in 2024, then plummeted by 100.55% to -$24,000 in 2025.
  • Its last three reported values are -$24,000 in Q3 2025, $93,000 for Q2 2025, and -$402,000 during Q1 2025.